36-month bone mineral density results in women treated with elagolix + add-back therapy for heavy menstrual bleeding associated with uterine fibroids

To evaluate the long-term (36-month) effect of elagolix 300 mg twice daily in combination with add-back therapy (estradiol 1 mg/norethindrone acetate 0.5 mg; ELA+AB) on bone mineral density (BMD) in premenopausal women treated for HMB associated with UF enrolled in an ongoing phase 3b, 48-month study for UF-associated HMB (NCT03271489).

https://www.fertstert.org/article/S0015-0282(23)01410-3/fulltext?rss=yes

Source: Fertility and Sterility - October 1, 2023 Category: Reproduction Medicine Authors: Vicki L. Schnell, Juki Ng, Eric Brown, Liesl K. Bredeson, James W. Thomas, Anna Chan, Michael C. Snabes Source Type: research